What Is BPC-157? Benefits, Research & Safety

BPC-157 was first isolated and characterised by Professor Predrag Sikirić and his research team at the University of Zagreb, Croatia, in the early 1990s. The peptide was derived from a larger protective protein identified in human gastric juice, which demonstrated remarkable cytoprotective properties. Initial research focused on the gastro-protective capabilities of the compound, with early studies demonstrating its ability to protect against various forms of gastrointestinal damage including ulcers, inflammatory bowel conditions, and mucosal lesions. The name "Body Protection Compound" reflects these early findings regarding its protective effects. Throughout the 1990s and 2000s, the research team in Zagreb expanded their investigations to explore BPC-157's effects beyond the gastrointestinal system. Studies began to emerge showing potential benefits for musculoskeletal injuries, leading to increased interest from the sports medicine and regenerative medicine research communities. The peptide sequence was patented, and over 100 research papers have been published examining various aspects of BPC-157's biological activity. While the majority of research has been conducted in animal models, the consistent positive findings across numerous studies have generated considerable interest in potential clinical applications. Research continues to this day, with ongoing investigations into the peptide's mechanisms of action and potential therapeutic applications across a range of conditions.